Target Safety Assessment & Target Intelligence
Target Safety Assessment is essential for the success of your toxicology studies. Understanding your target early in drug development will ensure that you can de-risk your target, reduce the cost of your of toxicology studies and reduce the time spent in the preclinical stage.
At Metisox we can provide precision insights for your target(s) and you will receive a complete Target Profile. This includes target safety assessment, target intelligence, mechanistic driven drug discovery and identification of potential safety biomarker candidates. Our proprietary AI tools, machine learning and clinical data sources can search unexplored areas of biology to identify potential adverse effects, new targets for your pipeline as well as target repurposing options.
Metisox offers these as a complete package or as separate modules depending on your requirements and stage of your project.
Join our Webinar: Mini-Target Safety Assessment (Mini-TSA)
9th December 2021 @5pm (GMT) / 12pm (EST) / 9am (PST)
In this webinar you will learn about:
- Challenges in target safety profiling and target safety related drug attrition
- Advantages of utilizing a mini-TSA early in your program
- Overview of a mini-Target Safety Assessment Report
Recently, we launched our new rapid and concise mini-TSA report that delivers known on-target toxicities and summarizes potential safety risks associated with modulation of your target within five days. Join our webinar and learn how these reports can be applied in your drug development process to de-risk your programs.
Target Safety Assessment Pipeline
Your TSA report will include the biology of target family, target function and involvement in human and animal diseases. The data is sourced from multiple types of data sources including several publicly available databases combined together with our proprietary SysWiz database. Metisox’s SysWiz database is utilised to extract multiomics intelligence; including mRNA and protein expression profiles, related proteins and intra- and inter- species variation.
Metisox has delivered TSA reports for targets from over 75% of all druggable families and looking forward to completing the whole family set with your target(s).
“Outsourcing our Target Safety Assessment Reports to Metisox, for the past 5 years, has helped speed up our toxicology investigations as well as provide insightful mitigation plans that we were unable to deduce from our internal resources”
– Study Director, Toxicology
Target Safety Assessment Reports (TSA Reports)
Metisox combines multiple data sources to deliver concise knowledge driven target safety assessment reports providing an intelligent safety profile of your target. The key output is a Risk Mitigation Plan that provides insights on your target and options to mitigate toxicology risks moving forward. This will include extensive knowledge for making informed decisions on your targets, ranking targets, de-risking strategies and/or designing investigative studies.
We offer three types of TSAs:
- Mini-TSA Report (Turnaround <5 days)
Provides insights rapidly for multiple targets following a screen
Useful for very early preclinical studies when there is limited data available
- Standard TSA Report (Turnaround <20 days)
Provides detailed insights for your lead target
Actionable summary of safety concerns included in executive summary
- Novel TSA Reports (Turnaround 5 – 20 days)
Utilises Metisox’s Precision Insights SysWiz database for predicting toxicology for novel targets
Deeper data mine compare to a Mini-TSA
Bulk discount offer – To learn more about our TSA Reports and/or request information on bulk discount options, please provide your details below: